Company profile: Harvard Apparatus Regenerative Technology
1.1 - Company Overview
Company description
- Provider of regenerative implant technologies using Cellspan scaffolds seeded with patients’ stem cells, including esophageal and bronchial implants to repair tubular structures and reduce complications; applications for digestive tract disorders and patch technologies for reproductive tract disorders; and a consumer medicine division offering longevity products for Asia’s aging population.
Products and services
- Cellspan Bronchial Implants: Patient-derived, cell-based implants repair the bronchus to preserve lung function, targeting fewer complications than traditional pneumonectomy using a patient's own cells
- Cellspan Esophageal Implants: Cell-seeded scaffold constructs regenerate the esophagus with a patient's own stem cells, intended to simplify surgical procedures and reduce complications via scaffold-guided tissue repair
- Cellspan Technology for Digestive Tract Disorders: Tubular-structure-focused applications repair digestive tract segments, including the colon, addressing complications from diseases or obstructions using Cellspan technology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Harvard Apparatus Regenerative Technology
New Haven Pharmaceuticals
HQ: United States
Website
- Description: Provider of prescription pharmaceuticals utilizing drugs or GRAS active pharmaceutical ingredients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full New Haven Pharmaceuticals company profile →
Xenetic Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drugs, cancer therapies and vaccines, centered on a DNase I oncology platform and NETs-targeting approaches for pancreatic and other solid tumors; collaborates with Volition on NETs-targeted adoptive cell therapies; holds sublicenses for PolyXen technology for blood/bleeding disorders and DNase enzyme-based cancer treatments; contracts cGMP manufacturing of recombinant Human DNase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenetic Biosciences company profile →
Ardea Biosciences
HQ: United States
Website
- Description: Provider of biotechnology development, headquartered in San Diego, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ardea Biosciences company profile →
Ablynx
HQ: Belgium
Website
- Description: Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablynx company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Harvard Apparatus Regenerative Technology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Harvard Apparatus Regenerative Technology
2.2 - Growth funds investing in similar companies to Harvard Apparatus Regenerative Technology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Harvard Apparatus Regenerative Technology
4.2 - Public trading comparable groups for Harvard Apparatus Regenerative Technology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →